U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469735) titled 'Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma' on March 05.
Brief Summary: The goal of this prospective, single-arm, open-label clinical trial is to evaluate whether 18F-AGX PET imaging can be used to assess early treatment response and metabolic changes in adult patients with recurrent or residual WHO 2021 grade 2-3 IDH-mutant diffuse glioma receiving Vorasidenib therapy.
IDH-mutant diffuse gliomas often show slow tumor growth, making early treatment response difficult to evaluate using conventional structural imaging such as magnetic resonance imaging (MRI). Clinical endpoints such as progression-free survival (PFS...